Jason Lohmueller News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

/PRNewswire/ Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy.

San diegoUnited statesSan diego convention centerDaniel kontoh boatengKarolinska institutetElisa ruffoDave mehalickJason lohmuellerSecurities exchangeCoeptis therapeutics incHoldings incExchange commissionCoeptis pharmaceuticals incDrug administrationCoeptis therapeutics holdings incDivision of surgical oncology research

Coeptis Therapeutics (COEP) Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Coeptis Therapeutics (COEP) Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jason lohmuellerDaniel kontoh boatengDavid schemeliaKarolinska institutetVygen bioDave mehalickUniversity of pittsburghDivision of surgical oncology researchCoeptis pharmaceuticals incTiberend strategic advisors incCoeptis therapeutics holdings incDrug administrationExchange commissionSecurities exchangeCoeptis therapeutics incCoeptis therapeutics holdings

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

/PRNewswire/ Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy.

Jason lohmuellerKarolinska institutetVygen bioDaniel kontoh boatengDave mehalickDavid schemeliaCoeptis therapeutics incSecurities exchangeUniversity of pittsburghDivision of surgical oncology researchCoeptis therapeutics holdings incHoldings incExchange commissionPrnewswire coeptis therapeutics holdings incDrug administrationCoeptis pharmaceuticals inc

Coeptis Therapeutics Supercharges Licensing Agreement with University of Pittsburgh to Unleash SNAP-CAR NK Cell Technology

According to a recent press release, Coeptis Therapeutics Holdings, Inc. has expanded its exclusive licensing agreement with the University of Pittsburgh

Jason lohmuellerVygen bioDave mehalickCoeptis therapeutics holdings incUniversity of pittsburghCoeptis therapeutics holdingsDeverra therapeuticsCoeptis therapeuticsAssistant professorTherapeutics holdingsCoeptis therapeutic

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer s 38th Annual Meeting

/PRNewswire/ Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy.

San diegoUnited statesSan diego convention centerDave mehalickDaniel kontoh boatengKarolinska institutetJason lohmuellerSociety for immunotherapy of cancerExchange commissionDrug administrationCoeptis therapeutics incPrnewswire coeptis therapeutics holdings incSecurities exchangeUniversity of pittsburghCoeptis therapeutics holdings incHoldings inc